On July 26, Oracle rolled out Oracle Pedigree and
Serialization Manager, an application that allows pharmaceutical
manufacturers to track drugs through the supply chain, limit
counterfeit medication and conform with California state regulations on
the sale of medication.
Pedigrees are electronic records that track the
sale of a potentially harmful drug by a manufacturer and follow it
through to the wholesaler, manufacturer and pharmacy.
A California drug pedigree passed in March 2008
will require electronic documentation by 2015 of all drugs sold,
manufactured or distributed in the state.
"I don't think that manufacturers are going to be
let off the hook," Gregg Malkary, founder and managing director of
Spyglass Consulting Group, told eWEEK. "It does require them to make a
lot of investments, but certain regulatory agencies are requiring
organizations to provide better support of pedigrees."
Protecting a company's bottom line is also an
essential consideration along with regulatory compliance for pedigree
apps, according to Jon Chorley, vice president of SCM Product Strategy
for Oracle.
"Ensuring supply chain integrity is not only about
compliance and protecting your brand, it's also about protecting your
bottom line," Chorley said in a statement. "By definitively identifying
your products in the supply chain and providing a broad set of analytic
insights on that data, Oracle Pedigree and Serialization Manager will
deliver both. The result is a safe and secure pharmaceutical supply
chain, combined with a strong ROI."
Malkary agreed with the assessment of strong ROI potential for drug pedigree applications.
"It not only improves ROI but also improves
patient safety because it improves the integrity of what the drugs are
supposed to be," Malkary said. "Patient safety is a huge issue."
According to Malkary, Viagra and OxyContin are the two most counterfeited drugs on the market.
Oracle's drug pedigree application will also help protect the legitimacy of returned products.
In addition, the software conforms to global
regulations for managing the serialization of pharmaceuticals. It also
supports the GS1 SGTIN (Serialized Global Trade Identification) format.
"Certainly as it moves through the supply chain,
there's a greater need to have increased or improved documentation as
medications change ownership from one distributor to another," Malkary
said. "Some pharmacies are repackaging medications from scratch so they
have a uniform way of prescribing them in the hospital."
Oracle ePedigree application is built on the
company's Fusion SOA (service-oriented architecture) platform, the
foundation for Oracle's enterprise service applications. The pedigree
application uses RFID technology to track pharmaceutical products.
The company's announcement comes as counterfeit
drugs continue to be a global problem. In November 2009, the Council of
Europe drafted a treaty calling for more cooperation in the fight
against counterfeit drugs.
IBM is also in the drug-pedigree market with its InfoSphere Traceability Server and WebSphere RFID products.
In a blog post, IDC analyst Eric Newmark predicted
last fall when Oracle announced it would launch this application that
the enterprise IT giant would become a leading drug pedigree provider
by 2011.